Empagliflozin (JARDIANCE®) is proven to go beyond lowering A1C to reduce the risk of CV death for adults who have type 2 diabetes and heart disease

Empagliflozin (JARDIANCE^®) is proven to go beyond lowering A1C to reduce the risk of CV death for adults who have type 2 diabetes and heart disease

Empagliflozin (JARDIANCE)'s Consistent CV and Renal Benefits in HFrEF

Document ID: PC-PH-103702

04/07/2022

Author: Boehringer Ingelheim

Related content